Heart failure as an independent predictor of thrombus persistence in nonvalvular atrial fibrillation: a transesophageal echocardiography-based study

Ewelina Kowalczyk, Jaroslaw D. Kasprzak, Piotr Lipiec

Department of Cardiology, Medical University of Lodz, Lodz, Poland

ABSTRACT

INTRODUCTION  Formation of left atrial (LA) thrombus is one of the most serious complications in patients with atrial fibrillation (AF).

OBJECTIVES  The aim of our study was to determine the predictors of LA thrombus resolution among patients with AF receiving oral anticoagulation.

PATIENTS AND METHODS  After a retrospective analysis of 1877 transesophageal echocardiographic examinations (TEEs) performed in our department between January 2009 and June 2013, we included 64 patients (women, 36%; mean age at diagnosis, 64 ±8.8 years) with nonvalvular AF and LA thrombi on TEE into the study. All patients received oral anticoagulation and underwent follow-up TEE within a few months since diagnosis.

RESULTS  After a mean follow-up period of 88 ±107 days, thrombus resolution was observed in 30 patients (47%). The univariate Cox proportional regression model showed that heart failure and reduced left ventricular ejection fraction were associated with the persistence of LA thrombus (hazard ratio [HR], 2.72; 95% confidence interval [CI], 1.32–5.61; \(P = 0.007\) and HR, 0.97; 95% CI, 0.94–0.99; \(P = 0.04\); respectively). The international normalized ratio and CHA2DS2-VASc score were not prognostic for thrombus resolution (HR, 0.64; 95% CI, 0.37–1.1; \(P = 0.1\) and HR 1.10; 95% CI, 0.91–1.33; \(P = 0.3\); respectively). In a multivariate analysis, heart failure was the only independent factor predicting unsuccessful resolution of LA thrombus (\(P = 0.04\)).

CONCLUSIONS  Heart failure is an independent negative predictor of LA thrombus resolution in patients with AF receiving oral anticoagulation.

INTRODUCTION  Formation of left atrial (LA) thrombus is an unfavorable scenario in patients with atrial fibrillation (AF). Patients referred for cardioversion and diagnosed with LA thrombus undergo intensive anticoagulant treatment for at least 3 to 4 weeks, followed by repeated transesophageal echocardiography (TEE). However, such a strategy does not guarantee thrombus resolution—the reported prevalence of LA thrombi assessed by TEE in a population of patients with AF receiving oral anticoagulation ranges from 1.1% to 8.8% (depending on whether the international normalized ratio [INR] levels were optimal or subtherapeutic), and the success rate is 90%. To our knowledge, there have been no studies providing information about predictors of LA thrombus resolution.

PATIENTS AND METHODS  Study population  Based on a retrospective analysis of 1877 TEEs performed in our department between January 2009 and June 2013, we identified 74 patients with LA thrombus (3.9%). The final study sample included 64 patients with nonvalvular AF and LA thrombi detected on TEE (23 women, 41 men) who subsequently received oral anticoagulant therapy and underwent follow-up TEE in our institution. The main indications for baseline
TABLE 1 Baseline characteristics of the study population (n = 64)

| Variable                        | Value     |
|---------------------------------|-----------|
| age, y                          | 64 ± 8.8  |
| follow-up, d                    | 88 ± 107  |
| male sex                        | 41 (64)   |
| left atrial appendage thrombus   | 59 (92)   |
| heart failure                   | 27 (42)   |
| arterial hypertension           | 35 (55)   |
| mitral valve stenosis           | 0 (0)     |
| mitral valve insufficiency, grade I (mild) | 22 (34) |
| mitral valve insufficiency, grade II (moderate) | 7 (11)   |
| diabetes mellitus               | 14 (22)   |
| coronary artery disease         | 18 (28)   |
| obesity                         | 18 (28)   |

Data are presented as mean ± standard deviation or number (percentage).

TEE were AF, suspected heart failure or chronic heart failure, and stable coronary artery disease. The past medical history, baseline clinical characteristics on admission to the hospital, and 12-lead electrocardiography findings were obtained from medical charts archived in our database. Heart failure was defined clinically in accordance with the European Society of Cardiology (ESC) guidelines. After the diagnosis of LA thrombus, all patients received oral anticoagulation with vitamin K antagonist (acenocoumarol, warfarin) and underwent follow-up TEE and INR measurements.

The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Patients gave written informed consent before each TEE.

Echocardiographic assessment All patients underwent conventional transthoracic echocardiography and TEE performed with VIVID7 Dimension (GE Vingmed Ultrasound AS, Hurten, Norway) using the harmonic mode. Both examinations were performed by certified echocardiographers. Left ventricular ejection fraction (LVEF) was calculated using the modified Simpson’s biplane method. TEEs were focused on the visualization of LA thrombi. Thrombus was defined as a well-circumscribed, intracavitary, echogenic mass distinct from the atrial endocardium or pectinate muscles and visible in multiple planes; the convex contour was used as a criterion for differentiation with spontaneous echocardiographic contrast. Statistical analysis The MedCalc version 10.4.8.0 statistical software package (MedCalc, Mariakerke, Belgium) was used for all statistical calculations. Continuous variables were presented as mean ± standard deviation and categorical variables—as percentages. Cox proportional hazard regression models were used to identify predictors of thrombus resolution, and independent predictors were determined by the multiple regression method. A P value of less than 0.05 was considered statistically significant.

RESULTS The baseline characteristics of the patients are summarized in Table 1. The prevalence of reduced LVEF (≤40%) was 42%.

After a mean follow-up period of 88 ± 107 days, thrombus resolution was documented in 30 patients (47%). The Cox proportional regression model showed that heart failure and LVEF were predictors of LA thrombus persistence (hazard ratio [HR], 2.72; 95% confidence interval [CI], 1.32–5.61; P = 0.007 and HR, 0.97; 95% CI, 0.94–0.99; P = 0.04; respectively).

Interestingly, the INR level and CHA2DS2-VASc score were not significantly associated with thrombus resolution (HR, 0.64; 95% CI, 0.37–1.1; P = 0.1, and HR 1.10; 95% CI, 0.91–1.33; P = 0.3; respectively). The prognostic value of the studied variables is summarized in Table 2. The multiple regression method indicated heart failure to be an independent predictor of unsuccessful LA thrombus resolution (P = 0.04).

DISCUSSION Our study indicated that heart failure and low LVEF decrease the chance for thrombus resolution in patients with nonvalvular AF. This is an important finding because there is a paucity of data regarding the prognostic factors for successful resolution of LA appendage thrombus in AF. Our findings can be used to guide clinical decision making in terms of when to initiate short-term high-intensity anticoagulation in patients who are more likely to have their thrombus resolved. The predictive utility of heart failure in thrombus resolution was also documented by Silakur et al., but in a different population. In their study, among 108 patients referred for percutaneous transvenous mitral commissurotomy with diagnost LA thrombus, the clinical New York Heart Association functional class was found to be an independent predictor.

In our study, the resolution of thrombus after anticoagulant therapy with vitamin K antagonist was reported in 47% of the cases. Previous studies described thrombus resolution even in 62% or 80.1% of the patients. These discrepancies may result from the differences in the baseline characteristics of the study populations. Our population was older and more often showed reduced LVEF (≤40%).

It should also be noted that 3 weeks of anticoagulant therapy, even with the therapeutic INR level, may not be sufficient for thrombus resolution. The study of Seidl et al. compared 2 strategies before cardioversion: effective anticoagulation (INR of 2 or 3) lasting at least 3 weeks before cardioversion and TEE-guided cardioversion. The results showed that...
TABLE 2 Characteristics of the study subgroups depending on the outcome (group A, patients with thrombus resolution; group B, patients with persistent thrombus) with predictive value of the studied variables (according to logistic regression results)

| Characteristics of study groups | Statistical significance for outcome prediction |
|---------------------------------|-----------------------------------------------|
|                                 | group A | group B | P value | hazard ratio | odds ratio (95% CI) |
| spontaneous echo contrast        |         |         | 0.3     | 0.72         | 0.3556–1.4416      |
| maximum LA diameter, mm          | 47.1 ± 6.7 | 50.5 ± 5.8 | 0.1    | 1.05         | 0.9836–1.1283      |
| LV diastolic diameter, mm        | 52.1 ± 11.4 | 57.5 ± 10.4 | 0.08  | 1.02         | 0.9969–1.0596      |
| LV systolic diameter, mm         | 39.6 ± 2.6 | 44.7 ± 2.5 | 0.1    | 1.02         | 0.9958–1.0482      |
| mean LVEF, %                     | 44.3 ± 2.8 | 39.7 ± 15.3 | 0.04  | 0.97         | 0.9442–0.9978      |
| INR                              | 2.07 ± 1.85 | 2.29 ± 1.3 | 0.1    | 0.64         | 0.3720–1.1044      |
| CHA2DS2 ‑VASc score              | 2.8 ± 1.8 | 3.2 ± 1.6 | 0.3    | 1.10         | 0.9093–1.3277      |
| heart failure                    | 9 (30)   | 18 (53)  | 0.007  | 2.72         | 1.3189–5.6135      |
| diabetes mellitus                | 6 (20)   | 8 (23.5) | 0.4    | 1.43         | 0.6449–3.1646      |
| hypertension                     | 16 (53)  | 19 (55.9) | 0.6    | 1.18         | 0.6011–2.3327      |
| vascular disease                 | 9 (30)   | 13 (38.2) | 0.2    | 1.60         | 0.8018–3.2004      |

Data are presented as mean ± standard deviation or number (percentage).

Abbreviations: CI, confidence interval; INR, international normalized ratio; LA, left atrial; LV, left ventricular; LVEF, left ventricular ejection fraction.

the approaches were not significantly different in terms of patients’ outcomes after cardioversion and formed the basis for the American College of Chest Physicians guidelines as well as for the ESC guidelines. However, in the study by Siegl et al., the group of patients in whom anticoagulation was effective was characterized by a significantly lower prevalence of heart failure than that in our population. Therefore, we suggest a more common use of TEE before cardioversion for patients with heart failure or reduced LVEF (≤40%).

It should also be emphasized that in our group normal LVEF did not exclude the possibility of LA or LA appendage thrombus—17% of the patients with a LVEF of 50% or higher had an LA thrombus present. Interestingly, the literature provides conflicting results. Khan et al. studied 1221 patients with paroxysmal AF who received anticoagulation and found that none of the patients with normal LVEF (defined as LVEF exceeding 50%) had LA thrombus present on TEE.

Our study has several limitations. This was a single-center retrospective analysis with a varying duration of follow-up. An additional analysis of the size and echogenicity of the thrombus would considerably improve the predictability of its persistence. Diagnosis of heart failure may be affected by the coexistence of AF because many symptoms are similar. In our group, the INR was measured only once—on the first day of follow-up hospitalization. This may not reflect the real effectiveness of anticoagulant therapy. Nevertheless, most patients in our study had an INR at the therapeutic range. Finally, we did not analyze patients receiving novel oral anticoagulation, which is becoming increasingly common in the population with AF and has been shown, in some patients, to be successful in LA thrombus resolution.

In conclusion, heart failure is an independent negative predictor of LA thrombus resolution in patients receiving anticoagulant therapy.

Contribution statement All authors conceived the idea for the study, contributed to the design of the research, analyzed the data, and edited and approved the final version of the manuscript. EK was involved in data collection.

REFERENCES

1 European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31: 2369-2429.
2 Nagraharanti R, Zeewitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011; 123: 131-136.
3 Fukuda S, Watanabe H, Shimada K, et al. Left atrial thrombus and prognosis after anticoagulation therapy in patients with atrial fibrillation. J Cardiol. 2011; 58: 266-277.
4 Maltagliati A, Pepi M, Tamborini G, et al. Usefulness of multiplane transesophageal echocardiography in the recognition of artifacts and normal anatomical variants that may mimic left atrial thrombi in patients with atrial fibrillation. Ital Heart J. 2003; 4: 787-802.
5 Seidl K, Rameken M, Drügemüller A, et al. Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen Observational Cardioversion Study. J Am Coll Cardiol. 2002; 39: 1426-1442.
6 Saeed M, Rahman A, Afzal A, et al. Role of transesophageal echocardiography guided cardioversion in patients with atrial fibrillation, previous left atrial thrombus and effective anticoagulation. Int J Cardiol. 2006; 113: 401-405.
7 Collins LJ, Silverman DI, Douglas PS, Manning WJ. Cardioversion of nonhemorrhagic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. Circulation. 1995; 92: 160-163.
8 McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33: 1707-1847.
9 Pepi M, Evangelista A, Nihoyannopoulos P, et al. European Association of Echocardiography. Recommendations for echocardiography use in the diagnosis and management of cardiac sources of embolism: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr. 2010; 11: 461-478.
Kanagala P, Bradley C, Hoffman P, Steeds RP; British Society of Echocardiography. Guidelines for transoesophageal echocardiographic probe cleaning and disinfection from the British Society of Echocardiography. Eur J Echocardiogr. 2011; 12: 17-23.

Silaruks S, Thinkhamrop B, Tantikosum W, et al. A prognostic model for predicting the disappearance of left atrial thrombi among candidates for percutaneous transvenous mitral commissurotomy. J Am Coll Cardiol. 2002; 39: 886-891.

Jaber WA, Prior DL, Thamarasan M, et al. Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: A transoesophageal echocardiographic study. Am Heart J. 2000; 140: 150-156.

He H, Kang J, Tao H, et al. Conventional oral anticoagulation may not replace prior transoesophageal echocardiography for the patients with planned catheter ablation for atrial fibrillation. J Interv Card Electrophysiol. 2009; 24: 19-26.

Sedl K, Hauer B, Schwigg NG, et al. Risk of thromboembolic events in patients with atrial flutter. Am J Cardiol. 1998; 82: 580-583.

Singer DE, Albers GW, Dalen JE, et al. American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008; 133: 546S-592S.

Khan MN, Usmani A, Noor S, et al. Low incidence of left atrial or left atrial appendage thrombus in patients with paroxysmal atrial fibrillation and normal EF who present for pulmonary vein antrum isolation procedure. J Cardiovasc Electrophysiol. 2008; 19: 356-358.

Bernhardt P, Schmidt H, Hammerstingl C, et al. Atrial thrombi-a prospective follow-up study over 3 years with transesophageal echocardiography and cranial magnetic resonance imaging. Echocardiography. 2006; 23: 388-394.

Riva N, Lip GY. A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long-term prevention of thromboembolic complications in patients with atrial fibrillation? Pol Arch Med Wewn. 2012; 122: 45-53.

Kis Z, Földesi C, Pál M, et al. Percutaneous left atrial appendage closure after resolution of left atrial appendage thrombi with dabigatran. Orv Hetil. 2013; 154: 262-265.

Vidal A, Vanerio G. Dabigatran and left atrial appendage thrombus. J Thromb Thrombolysis. 2012; 34: 545-547.
ARTYKUŁ ORYGINALNY

Niewydolność serca jako niezależny czynnik predykcyjny utrzymywania się skrzepliny u pacjentów z migotaniem przedsiomków – badanie w oparciu o echokardiografię przepiętkową

Ewelina Kowalczyk, Jarosław D. Kasprzak, Piotr Lipiec
Klinika Kardiologii, Uniwersytet Medyczny w Łodzi, Łódź

SŁOWA KLUCZOWE
rozpuszczenie skrzepliny, skrzeplina lewego przedsiomka, skrzeplina uszka lewego przedsiomka

STRESZCZENIE

WProwadzenie Obecność skrzepliny w lewym przedsiomku serca jest jednym z najpoważniejszych powikłań migotania przedsiomków (AF).

Cel Celem badania była ocena czynników progностycznych zanikania skrzeplin w lewym przedsiomku wśród pacjentów z AF otrzymujących doustne leczenie przeciwickrępliwe.

Pacjenci i metody Retrospektywna analiza bazy 1877 badań TEE wykonanych w naszej klinice pomiędzy styczniem 2009 roku i czerwcem 2013 roku, pozwoliła na włączenie do badania grupy 64 pacjentów (36% kobiet, średni wiek w chwili diagnozy 64 ± 8,8 lat) z migotaniem przedsiomków oraz zdiagnozowaną w TEE skrzepliną lewego przedsiomka. Wszyscy chorzy otrzymywali doustne leczenie przeciwickrępliwe (antagoniści witaminy K) oraz w przeciągu kilku miesięcy od chwili diagnozy mieli wykonane kontrolne badanie TEE.

Wyniki Po średnim okresie obserwacji 88 ±107 dni zaniknięcie skrzepliny zaobserwowano u 30 pacjentów (47%). Jednoczynnikowy model regresji Coxa wykazał, że niewydolność serca oraz obniżona frakcja wyrzutowa lewej komory wiąże się z utrzymywaniem się skrzeplin w lewym przedsiomku (odpowiednio: HR 2,72; 95% CI 1,32–5,61; p = 0,007 i HR 0,97; 95% CI 0,94–0,99; p = 0,04). Międynarodowy współczynnik znormalizowany oraz skala CHA₂DS₂-VASc nie miały wartości progностycznej dla rozpuszczenia skrzepliny (odpowiednio: HR 0,64; 95% CI 0,37–1,1; p = 0,1 i HR 1,10; 95% CI 0,91–1,33; p = 0,3). Analiza wieloczynnikowa wskazała niewydolność serca jako jedyny niezależny czynnik progностyczny nieskuteczności rozpuszczania skrzepliny (p = 0,04).

Wnioski Niewydolność serca jest niezależnym czynnikiem predykcyjnym utrzymywania się skrzepliny lewego przedsiomka wśród pacjentów z migotaniem przedsiomków otrzymujących doustne leczenie przeciwickrępliwe.